Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...
- Preferred shares issued in recently completed $103M financing to convert to common shares - - Gilead to become shareholder in Sierra in accordance with amendment to Purchase Agreement -...
- New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefits in myelofibrosis presented in a poster at the 61st American Society of Hematology Annual Meeting - - Analyst &...
View all news releases
Building Momentum for Patients with Myelofibrosis – Q1 2020
View All Presentations
Hyatt Regency Orlando, Bayhill 33 Meeting Room
Toll-Free: 1 (844) 467-7642
Toll: 1 (417) 385-2994
Conference ID: 3577956
View all events and webcasts
James Smith, Vice President Corporate Affairs
Sign up for investor alerts